康众医疗(688607) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 50,118,994.79, representing a year-on-year increase of 31.58%[5] - The net profit attributable to shareholders was a loss of CNY 6,696,810.56, with a basic earnings per share of -0.08 yuan[5][6] - The company reported a net loss for Q1 2023, with total costs exceeding total revenue, indicating challenges in managing operational expenses[17] - The net profit for Q1 2023 was -6,670,634.06 RMB, compared to -7,232,998.53 RMB in Q1 2022, showing an improvement of approximately 7.8%[18] - The company reported a comprehensive loss of -7,755,168.80 RMB in Q1 2023, compared to -7,035,964.29 RMB in Q1 2022, indicating a decline of about 10.2%[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 900,801,285.14, a decrease of 0.21% compared to the end of the previous year[6] - Total assets amounted to RMB 900,801,285.14 as of March 31, 2023, slightly down from RMB 902,683,287.61 at the end of 2022[15] - Total liabilities increased to RMB 64,399,619.76 as of March 31, 2023, compared to RMB 58,526,453.43 at the end of 2022, reflecting an increase of 10.5%[16] - The company's equity attributable to shareholders decreased to RMB 836,421,291.38 as of March 31, 2023, down from RMB 844,202,636.68 at the end of 2022[16] Cash Flow - The company experienced a cash flow from operating activities loss of CNY 16,390,474.84[5] - Cash flow from operating activities showed a net outflow of -16,390,474.84 RMB in Q1 2023, an improvement from -18,775,283.32 RMB in Q1 2022[21] - The cash and cash equivalents at the end of Q1 2023 were 184,502,195.11 RMB, down from 216,869,303.99 RMB at the end of Q1 2022, a decrease of approximately 14.9%[23] - The investment activities resulted in a net cash outflow of -1,236,812.67 RMB in Q1 2023, compared to -118,933,422.09 RMB in Q1 2022, indicating a substantial reduction in cash outflow[23] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 58,245,493.04, up from RMB 48,810,062.03 in Q1 2022, reflecting a year-over-year increase of 19.8%[17] - Research and development expenses totaled CNY 12,318,360.85, accounting for 24.58% of revenue, a decrease of 3.70 percentage points year-on-year[6] - Research and development expenses increased to 12,318,360.85 RMB in Q1 2023, up from 10,773,753.92 RMB in Q1 2022, reflecting a growth of approximately 14.3%[18] - The company incurred financial expenses of 1,236,356.97 RMB in Q1 2023, significantly higher than 88,717.06 RMB in Q1 2022, marking an increase of over 1,300%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,227[10] - Liu Jianqiang, an overseas natural person, held 14.54% of the shares, amounting to 12,810,000 shares[10] Strategic Focus - The company actively addressed internal and external uncertainties, leading to revenue growth through new products and technology implementations[8] - The company is focusing on expanding its market presence and enhancing product development to drive future growth[12]